Eliem Therapeutics, Inc.ELYMNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +147.55% | +142.80% | +144.09% | +1.20% | +1.48% |
| Weighted Average Shares Diluted Growth | +147.55% | +142.80% | +144.09% | +1.20% | +1.48% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -316.48% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -316.48% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -48.49% | -100.00% | -100.00% | +0.00% | -100.00% |
| Inventory Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +97.10% | +96.60% | +83.60% | -14.88% | -17.95% |
| Book Value per Share Growth | -19.47% | -18.90% | -25.53% | -17.42% | -20.27% |
| Debt Growth | -87.36% | +52.44% | +110.67% | +539.00% | +900.00% |
| R&D Expense Growth | +111.65% | +185.00% | +1488.18% | +528.59% | +49.06% |
| SG&A Expenses Growth | +158.45% | +323.51% | +197.34% | +11.86% | +5.95% |